.Pharmacolibrary.Drugs.D_Dermatologicals.D06A_AntibioticsForTopicalUse.D06AX01_FusidicAcid.FusidicAcid .Pharmacolibrary.Drugs.D_Dermatologicals.D06A_AntibioticsForTopicalUse.D06AX01_FusidicAcid.FusidicAcid| name: | FusidicAcid |
| ATC code: | D06AX01 | route: | oral |
| n-compartments | 1 |
Fusidic acid is a steroidal antibiotic mainly used to treat skin and soft tissue infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved and widely used in topical, oral, and intravenous formulations, particularly in Europe and some other countries, although it is less commonly used in the United States.
Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.
Bulitta, JB, et al., & Ambrose, PG (2013). Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrobial agents and chemotherapy 57(1) 498–507. DOI:10.1128/AAC.01354-12 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23147726
Marsot, A, et al., & Blin, O (2017). Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. British journal of clinical pharmacology 83(5) 1039–1047. DOI:10.1111/bcp.13178 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27813241
Marsot, A, et al., & Guilhaumou, R (2020). Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. British journal of clinical pharmacology 86(11) 2319–2324. DOI:10.1111/bcp.14319 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32330996